Two-thirds of MASLD patients who qualify for a statin don't get one — mostly over a hepatotoxicity fear with no current evidential basis.
New review: why the liver may do more with statins than merely tolerate them.
@IDIVALdecilla@sepdigestiva
🔗 https://t.co/RAsG47x9yd